Key Insights

Highlights

Success Rate

75% trial completion

Treatment Research

12 treatments under study, led by Questionnaire

Research Leaders

12 sponsors active, led by Imperial College London

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 27/100

Termination Rate

14.3%

1 terminated out of 7 trials

Success Rate

75.0%

-11.6% vs benchmark

Late-Stage Pipeline

43%

3 trials in Phase 3/4

Results Transparency

67%

2 of 3 completed with results

Key Signals

2 with results75% success

Data Visualizations

Phase Distribution

5Total
Not Applicable (1)
Phase 2 (1)
Phase 3 (1)
Phase 4 (2)

Trial Status

Completed3
Not Yet Recruiting1
Unknown1
Terminated1
Recruiting1

Trial Success Rate

75.0%

Benchmark: 86.6%

Based on 3 completed trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT06317675Phase 2TerminatedPrimary

Osteopathic Manipulative Treatment for Gastro-oesophageal Reflux Disease

NCT07093359Phase 3RecruitingPrimary

LINX vs Fundoplication

NCT06664008Phase 4Not Yet RecruitingPrimary

The Effect of Probiotic and Zinc Supplementation in Patients With Gastroesophageal Reflux Disease

NCT06615856Unknown

The Influence of Concomitant Irritable Bowel Syndrome on Gastro-Oesophageal Reflux Disease Symptoms and Severity.

NCT03793556Not ApplicableCompletedPrimary

Evaluation of GERDOFF Efficacy in Combination With Proton Pump Inhibitor

NCT01507298CompletedPrimary

Physical Activity and Gastrointestinal Investigations

NCT00384592Phase 4CompletedPrimary

PPI Sequencing Study

Showing all 7 trials

Research Network

Common Treatments

  • Questionnaire1
  • Laparoscopic Or Robotic Fundoplication1
  • Ppi Proton Pump Inhibitor1
  • Omeprazole1
  • Probiotic1

Active Sponsors

  • Imperial College London2
  • AstraZeneca1
  • The Leeds Teaching Hospitals NHS Trust1
  • University of Bristol1
  • University of Oxford1

Top Investigators

Related Conditions

  • Irritable Bowel Syndrome1

Activity Timeline